Table 1.

Comparison of the effects of each drug combination with the individual drugs in the breast (MDA-MB-231 and MCF-7) and ovarian (HEY-T30 and SKOV-3) cancer cell lines in the drug-mediated inhibition of cell proliferation (MTT assay) and activation of apoptosis (Annexin V assay). p ≤ 0.05 is considered statistically significant.

Breast Cancer Cell Lines
MDA-MB-231						MCF-7
	Pano	SAHA	TLZ	OLA	DAC	Pano	SAHA	TLZ	OLA	DAC
Cell Proliferation
PTD	<0.0001		<0.0001		<0.0001	0.003		0.003		<0.0001
POD	<0.0001			<0.0001	<0.0001	0.003			0.0009	<0.0001
STD		<0.0001	<0.0001		<0.0001		0.0001	0.001		<0.0001
SOD		<0.0001		<0.0001	<0.0001		<0.0001		0.0002	<0.0001
Apoptosis
PTD	<0.0001		0.0001		<0.0001	0.011		0.068		0.014
POD	<0.0001			0.0001	0.0001	0.021			0.1	0.022
STD		<0.0001	0.0001		<0.0001		0.004	0.031		0.005
SOD		<0.0001		0.0001	0.0001		0.036		0.13	0.046
Ovarian Cancer Cell Lines
HEY-T30						SKOV-3
	Pano	SAHA	TLZ	OLA	DAC	Pano	SAHA	TLZ	OLA	DAC
Cell Proliferation
PTD	<0.0001		<0.0001		<0.0001	0.0004		<0.0001		<0.0001
POD	<0.0001			<0.0001	<0.0001	0.0008			<0.0001	<0.0001
STD		<0.0001	<0.0001		<0.0001		0.0005	0.0005		<0.0001
SOD		<0.0001		<0.0001	<0.0001		0.0008		0.0003	<0.0001
Apoptosis
PTD	0.0008		0.0003		0.001	0.037		0.001		<0.0001
POD	0.0101			0.0006	0.01	0.037			0.002	<0.0001
STD		0.0002	0.0003		0.001		0.002	0.003		<0.0001
SOD		0.004		0.0006	0.01		0.006		0.008	0.0001

Abbreviations: DAC: decitabine; OLA: olaparib; Pano: panobinostat; POD: panobinostat plus olaparib plus decitabine; PTD: panobinostat plus talazoparib plus decitabine; SAHA: vorinostat; SOD: SAHA (vorinostat) plus olaparib plus decitabine; STD: SAHA (vorinostat) plus talazoparib plus decitabine; TLZ: talazoparib.